CEL-SCI (NYSE:CVM) Trading Down 3.9%

CEL-SCI Co. (NYSE:CVM) dropped 3.9% during trading on Tuesday . The company traded as low as $1.65 and last traded at $1.71. Approximately 154,015 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 315,321 shares. The stock had previously closed at $1.78.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

CEL-SCI Stock Performance

The firm has a 50-day moving average price of $2.18 and a 200 day moving average price of $2.17. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $92.31 million, a PE ratio of -2.51 and a beta of 1.29.

CEL-SCI (NYSE:CVM) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. Research analysts expect that CEL-SCI Co. will post -0.48 earnings per share for the current year.

Institutional Trading of CEL-SCI

A number of hedge funds and other institutional investors have recently made changes to their positions in CVM. Price T Rowe Associates Inc. MD raised its position in shares of CEL-SCI by 23.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 19,800 shares of the company’s stock worth $89,000 after buying an additional 3,823 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of CEL-SCI by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 382,101 shares of the company’s stock valued at $897,000 after purchasing an additional 4,046 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of CEL-SCI by 195.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,280 shares of the company’s stock worth $37,000 after acquiring an additional 5,474 shares in the last quarter. Northern Trust Corp raised its stake in CEL-SCI by 7.2% during the 4th quarter. Northern Trust Corp now owns 83,864 shares of the company’s stock valued at $228,000 after purchasing an additional 5,629 shares during the period. Finally, Swiss National Bank raised its position in CEL-SCI by 7.4% during the first quarter. Swiss National Bank now owns 101,700 shares of the company’s stock valued at $400,000 after buying an additional 7,000 shares during the period. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.